Expiration Date: 04/04/2024
Learner Notification
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Speakers
Amanda Hammond PharmD, DABAT, MPH
Assistant Professor of Pharmacy Practice & Emergency Medicine Clinical Pharmacist
Arnold & Marie Schwartz College of Pharmacy & Health Sciences at Long Island University and Mount Sinai West Hospital
Has disclosed no relevant financial relationships
Faisal Syed Minhaj PharmD, DABAT, MPH
Emergency Medicine Clinical Pharmacist/Toxicologist
Wellstar Kennestone Hospital
Has disclosed no relevant financial relationships
Moderator
Alexandra R. Funk, PharmD, DABAT
Managing Director
Florida Poison Information Center – Tampa
Has disclosed no relevant financial relationships
Adam Overberg, MD
Managing Director, Indiana Poison Center
Indiana University Health Methodist Hospital
Has disclosed no relevant financial relationships
Organizer
David Vearrier, MD, MPH
Professor of Emergency Medicine
University of Mississippi Medical Center
Has disclosed no relevant financial relationships
Description
Drs. Hammond and Minhaj will discuss the following articles:
● Jon B. Cole, Samantha C. Lee, Matthew E. Prekker, Nathan M. Kunzler, Kelly A. Considine, Brian E. Driver, Michael A. Puskarich & Travis D. Olives (2022) Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines, Clinical Toxicology, 60:11, 1205-1213, DOI: 10.1080/15563650.2022.2131565
● Ola E. Nafea & Heba A. Hassan (2019) Comparative effectiveness of methylene blue versus intravenous lipid emulsion in a rodent model of amlodipine toxicity, Clinical Toxicology, 57:9, 784-789, DOI: 10.1080/15563650.2018.1560461
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives – After attending this program you should be able to:
- Describe the theoretical synergistic vasodilatory relationship between high dose insulin (HDI) therapy and amlodipine toxicity.
- Describe the impact of the relationship between high dose insulin (HDI) therapy and amlodipine toxicity in clinical treatment of CCB-poisoned patients.
- Recall the mechanism of toxicity and potential therapies for amlodipine toxicity.
- Compare the use of ILE in amlodipine poisoning in rats to other animal and human models of ILE use.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.
Click here to complete the Post Webinar CE Evaluation